Nanobioingeniería de sistemas terapéuticos y diagnósticos inteligentes

References

  • Turnbull A, Bermejo-Rodríguez C, Preston MA, Garrido-Barros M, Pimentel B, de la Cueva-Méndez G. Targeted cancer cell killing by highly selective miRNA-triggered activation of a prokaryotic toxin-antitoxin system. ACS Synth Biol. 2019 Jul 26. PMID: 31348648.
  • Preston MA, Pimentel B, Bermejo-Rodríguez C, Dionne I, Turnbull A, de la Cueva-Méndez G. Repurposing a Prokaryotic Toxin-Antitoxin System for the Selective Killing of Oncogenically Stressed Human Cells. ACS Synth Biol. 2016 Jul 15;5(7):540-6. PMID: 26230535.
  • de la Cueva-Méndez G, Seliktar D. Editorial overview: Pharmaceutical biotechnology: Expanding horizons for pharmaceutical biotechnology in industry and academia. Curr Opin Biotechnol. 2015 Dec;35:iv-vi. PMID: 26421602.
  • Núñez-Lozano R, Cano M, Pimentel B, de la Cueva-Méndez G. ‘Smartening’ anticancer therapeutic nanosystems using biomolecules. Curr Opin Biotechnol. 2015 Dec;35:135-40. PMID: 26277646.
  • Berraondo P, Aznar MA, Perez-Ruiz E, Rodriguez-Ruiz ME, Castañon E, Perez-Gracia JL, Melero I. International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain. Cancer Immunol Immunother. 2018 Nov;67(11):1809-1813. PMID: 30182281.
  • Collins GP, Rueda A, Salles G, von Tresckow B, Zaja F. Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries. Leuk Lymphoma. 2018 Sep;59(9):2113-2120. PMID: 29334819.
  • Pérez-Ruiz E, Rueda A, Pérez L, Rivas-Ruiz F, Torres E, de Luque V, Álvarez M, Sevilla I, Redondo M, Padilla-Ruiz M, Alba E, Alonso L. Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer. Pathol Oncol Res. 2018 Oct;24(4):871-879. PMID: 28889324.
  • García-Aranda M, Pérez-Ruiz E, Redondo M. Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy. Int J Mol Sci. 2018 Dec 8;19(12). PMID: 30544835.
  • Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, Sotelo MJ, Jaen A, Bayo JL, Carabantes F, Illarramendi JJ, Gordon MM, Cruz J, García-Palomo A, Mendiola C, Pérez-Ruiz E, Bofill JS, Baena-Cañada JM, Jáñez NM, Esquerdo G, Ruiz-Borrego M. Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. Clin Transl Oncol. 2018 Dec;20(12):1631-1632. PMID: 30284231.
  • Iglesias Docampo LC, Arrazubi Arrula V, Baste Rotllan N, Carral Maseda A, Cirauqui Cirauqui B, Escobar Y, Lambea Sorrosal JJ, Pastor Borgoñón M, Rueda A, Cruz Hernández JJ. SEOM clinical guidelines for the treatment of head and neck cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):75-83. PMID: 29159792.
  • Takeda M, Soliven B. Arachidonic acid inhibits myelin basic protein phosphorylation in cultured oligodendrocytes. Glia. 1997 Nov;21(3):277-84. PMID: 9383037.
  • Maañón J, Perez D, Rhode A, Callejón G, Rivas-Ruiz F, Perez-Ruiz E, Rodrigo I, Ramos B, Medina F, Villatoro R, Redondo M, Rueda A. High serum vascular endothelial growth factor C predicts better relapse-free survival in early clinically node-negative breast cancer. Oncotarget. 2018 Jun 15;9(46):28131-28140. PMID: 29963266.
  • Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, Torné A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Arance A, Prat A. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Ann Oncol. 2018 Oct 1;29(10):2121-2128. PMID: 30165419.
  • Rueda A, Calvo V, Casanova M, Rodriguez-Abreu D, Aguiar D, Llanos M, Alvarez R, Martinez-Banaclocha N, Alfaro J, Quero C, Blasco A, de la Cruz Merino L, Herrero J, García-Arroyo FR, Provencio M. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. Leuk Lymphoma. 2019 Jun;60(6):1576-1579. PMID: 30516082.
  • Álvaro Sanz E, Garrido Siles M, Rey Fernández L, Villatoro Roldán R, Rueda Domínguez A, Abilés J. Nutritional risk and malnutrition rates at diagnosis of cancer in patients treated in outpatient settings: Early intervention protocol. Nutrition. 2019 Jan;57:148-153. PMID: 30157469.
  • Fernández-Mateos J, Seijas-Tamayo R, Adansa Klain JC, Pastor Borgoñón M, Pérez-Ruiz E, Mesía R, Del Barco E, Salvador Coloma C, Rueda Dominguez A, Caballero Daroqui J, Fernández Ruiz E, Ocana A, González-Sarmiento R, Cruz-Hernández JJ. Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population. Cancers (Basel). 2019 Apr 7;11(4). PMID: 30959967.
  • González-Rincón J, Méndez M, Gómez S, García JF, Martín P, Bellas C, Pedrosa L, Rodríguez-Pinilla SM, Camacho FI, Quero C, Pérez-Callejo D, Rueda A, Llanos M, Gómez-Codina J, Piris MA, Montes-Moreno S, Bárcena C, Rodríguez-Abreu D, Menárguez J, de la Cruz-Merino L, Monsalvo S, Parejo C, Royuela A, Kwee I, Cascione L, Arribas A, Bertoni F, Mollejo M, Provencio M, Sánchez-Beato M. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. PLoS One. 2019 Feb 25;14(2):e0212813. PMID: 30802265.
  • Méndez M, Torrente M, Sánchez-Beato M, González-Rincón J, Royuela A, Gómez-Codina J, de la Cruz-Merino L, Rueda A, Llanos M, Quero C, Rodríguez-Abreu D, Gumá J, Monsalvo S, Sabin P, Provencio M. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group. Hematol Oncol. 2019 Apr;37(2):143-150. PMID: 30840776.
  • Padilla-Ruiz M, Ruiz-Román C, Pérez-Ruiz E, Rueda A, Redondo M, Rivas-Ruiz F. Clinical and sociodemographic factors that may influence the resilience of women surviving breast cancer: cross-sectional study. Support Care Cancer. 2019 Apr;27(4):1279-1286. PMID: 30607680.
  • Provencio M, Franco F, Gómez-Codina J, Quero Blanco C, Llanos M, Garcia-Arroyo F, de la Cruz L, Gumá J, Delgado JR, Álvarez R, Chacón JI, Royuela A, Rueda A. Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years. Leuk Lymphoma. 2019 Mar;60(3):856-859. PMID: 30234403.
  • Redondo M, Abitei C, Téllez T, Fúnez R, Pereda T, Rodrigo I, Betancourt AM, García-Aranda M, Rueda A, Martínez García RC, Morales Suarez-Varela MM, Zabalza I, Sánchez Del Charco M, Borrero Martín JJ, García Del Moral R, Escobar A, Quintana J, Rivas-Ruiz F; REDISSEC-CARESS/CCR group. Clinical-pathological characteristics and short-term follow-up associated with proliferation, apoptosis and angiogenesis in a prospective cohort of patients with colorectal tumours. Tumour Biol. 2019 Apr;42(4):1010428319835684. PMID: 30957671.
  • Alvarez M, Otano I, Minute L, Ochoa MC, Perez-Ruiz E, Melero I, Berraondo P. Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity. Cell Stress. 2019 Jun 27;3(7):236-239. PMID: 31309173.
  • Ochoa MC, Perez-Ruiz E, Minute L, Oñate C, Perez G, Rodriguez I, Zabaleta A, Alignani D, Fernandez-Sendin M, Lopez A, Muntasell A, Sanmamed MF, Paiva B, Lopez-Botet M, Berraondo P, Melero I. Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. Oncoimmunology. 2019 Apr 13;8(7):1599636. PMID: 31143521.
  • Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, de Andrea C, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I, Llacer C, Alvarez M, de Luque V, Molina C, Teijeira A, Berraondo P, Melero I. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019 May;569(7756):428-432. PMID: 31043740.

Lineas de Investigación

1. Desarrollo de terapias antitumorales inteligentes basadas en pares toxina-antitoxina.

2. Desarrollo de nanosistemas para la vehiculización dirigida de fármacos antitumorales y agentes de contraste in vivo.

3. Desarrollo de terapias antitumorales que actúen activando o inhibiendo las diferentes poblaciones celulares que conforman el microambiente inmune del tumor.

4. Búsqueda de factores/eventos biológicos predictivos de eventos clínicos (extensión de la enfermedad, marcadores de eficacia o toxicidad del tratamiento, marcadores de progresión/recidiva), especialmente en pacientes con cáncer sometidos a las nuevas terapias antitumorales de base inmunológica.



Proyectos de Investigación

PIGE-0539-2019. Desarrollo y evaluación pre-clínica de un sistema multimodal de diagnóstico por imagen mediante tomografía de emisión de positrones (PET), dirigible de forma selectiva hacia tejido tumoral y personalizable

Consejería de Salud y Familias
. 2019

Publicaciones científicas

  • Todo
  • D1
  • Q1
  • Q2
  • Otro
  1. Padilla-Ruiz, M, Ruiz-Román, C, Pérez-Ruiz, E, Rueda, A, Redondo, M, Rivas-Ruiz, F et al.. Clinical and sociodemographic factors that may influence the resilience of women surviving breast cancer: cross-sectional study. Support Care Cancer. 2019;27 (4):1279-1286. doi: 10.1007/s00520-018-4612-4. PubMed PMID:30607680 .
Search PubMed
  1. Godoy-Ortiz, A, Sanchez-Muñoz, A, Chica Parrado, MR, Álvarez, M, Ribelles, N, Rueda Dominguez, A et al.. Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. Front Oncol. 2019;9 :1124. doi: 10.3389/fonc.2019.01124. PubMed PMID:31737566 PubMed Central PMC6828840.
Search PubMed
  1. Téllez, T, García-Aranda, M, Zarcos-Pedrinaci, I, Rivas-Ruiz, F, Pérez Ruiz, E, Padilla-Ruiz, MDC et al.. First hospital contact via the Emergency Department is an independent predictor of overall survival and disease-free survival in patients with colorectal cancer. Rev Esp Enferm Dig. 2019;111 (10):750-756. doi: 10.17235/reed.2019.5777/2018. PubMed PMID:31345043 .
Search PubMed
  1. Álvarez Pérez, RM, Delgado García, A, García Martínez, S, Sanz Viedma, S, Palacios Gerona, H, Pajares Vinardel, M et al.. Four years of clinical experience with Radium-223 for the treatment of castration-resistant prostate cancer. Rev Esp Med Nucl Imagen Mol. ;38 (5):298-304. doi: 10.1016/j.remn.2019.04.004. PubMed PMID:31362912 .
Search PubMed
  1. Fernández-Mateos, J, Seijas-Tamayo, R, Adansa Klain, JC, Pastor Borgoñón, M, Pérez-Ruiz, E, Mesía, R et al.. Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population. Cancers (Basel). 2019;11 (4):. doi: 10.3390/cancers11040493. PubMed PMID:30959967 PubMed Central PMC6521206.
Search PubMed
  1. Díaz-Antonio, T, Sanz-Viedma, S, Delgado García, A, Roldán de la Rúa, J, Martínez Del Valle Torres, MD, Suárez Muñoz, MÁ et al.. Hepatobiliary scintigraphy with SPECT/CT IN the diagnosis of postsurgical biliopleural fistula. Gastroenterol Hepatol. 2019;42 (1):41-42. doi: 10.1016/j.gastrohep.2018.06.015. PubMed PMID:30177222 .
Search PubMed
  1. Zarcos-Pedrinaci, I, Redondo, M, Louro, J, Rivas-Ruiz, F, Téllez, T, Pérez, D et al.. Impact of adjuvant chemotherapy on the survival of patients with breast cancer diagnosed by screening. Cancer Med. 2019;8 (15):6662-6670. doi: 10.1002/cam4.2488. PubMed PMID:31549794 PubMed Central PMC6825992.
Search PubMed
  1. Ramchandren, R, Domingo-Domènech, E, Rueda, A, Trněný, M, Feldman, TA, Lee, HJ et al.. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. J Clin Oncol. 2019;37 (23):1997-2007. doi: 10.1200/JCO.19.00315. PubMed PMID:31112476 PubMed Central PMC6688776.
Search PubMed
  1. Álvaro Sanz, E, Garrido Siles, M, Rey Fernández, L, Villatoro Roldán, R, Rueda Domínguez, A, Abilés, J et al.. Nutritional risk and malnutrition rates at diagnosis of cancer in patients treated in outpatient settings: Early intervention protocol. Nutrition. 2019;57 :148-153. doi: 10.1016/j.nut.2018.05.021. PubMed PMID:30157469 .
Search PubMed
  1. Perez-Ruiz, E, Minute, L, Otano, I, Alvarez, M, Ochoa, MC, Belsue, V et al.. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569 (7756):428-432. doi: 10.1038/s41586-019-1162-y. PubMed PMID:31043740 .
Search PubMed
  1. Noriega-Álvarez, E, Domínguez Gadea, L, Orduña Diez, MP, Peiró Valgañón, V, Sanz Viedma, S, García Jiménez, R et al.. Role of Nuclear Medicine in the diagnosis of musculoskeletal infection: a review. Rev Esp Med Nucl Imagen Mol. ;38 (6):397-407. doi: 10.1016/j.remn.2019.06.001. PubMed PMID:31488365 .
Search PubMed
  1. Turnbull, A, Bermejo-Rodríguez, C, Preston, MA, Garrido-Barros, M, Pimentel, B, de la Cueva-Méndez, G et al.. Targeted Cancer Cell Killing by Highly Selective miRNA-Triggered Activation of a Prokaryotic Toxin-Antitoxin System. ACS Synth Biol. 2019;8 (8):1730-1736. doi: 10.1021/acssynbio.9b00172. PubMed PMID:31348648 .
Search PubMed
  1. Méndez, M, Torrente, M, Sánchez-Beato, M, González-Rincón, J, Royuela, A, Gómez-Codina, J et al.. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group. Hematol Oncol. 2019;37 (2):143-150. doi: 10.1002/hon.2601. PubMed PMID:30840776 .
Search PubMed
  1. González-Rincón, J, Méndez, M, Gómez, S, García, JF, Martín, P, Bellas, C et al.. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. PLoS One. 2019;14 (2):e0212813. doi: 10.1371/journal.pone.0212813. PubMed PMID:30802265 PubMed Central PMC6388933.
Search PubMed
  1. Sanz Viedma, S, Orcajo Rincón, J. A step forward in radiometabolic treatment of bone metastases with 223Ra. Rev Esp Med Nucl Imagen Mol. ;37 (5):271-272. doi: 10.1016/j.remn.2018.07.004. PubMed PMID:30097277 .
Search PubMed
  1. Martínez-Valle Torres, MD, Ramos Moreno, E, Amrani Raissouni, T, Sanz Viedma, S, Delgado Garcia, A, Jiménez-Hoyuela Garcia, JM et al.. A rare case of double parathyroid adenoma evidenced by 99mTc-sestaMIBI SPECT/CT. Rev Esp Med Nucl Imagen Mol. ;36 (1):57-58. doi: 10.1016/j.remn.2016.02.002. PubMed PMID:26992641 .
Search PubMed
  1. Cano, M, Núñez-Lozano, R, Lumbreras, R, González-Rodríguez, V, Delgado-García, A, Jiménez-Hoyuela, JM et al.. Partial PEGylation of superparamagnetic iron oxide nanoparticles thinly coated with amine-silane as a source of ultrastable tunable nanosystems for biomedical applications. Nanoscale. 2017;9 (2):812-822. doi: 10.1039/c6nr07462f. PubMed PMID:27982150 .
Search PubMed
  1. Preston, MA, Pimentel, B, Bermejo-Rodríguez, C, Dionne, I, Turnbull, A, de la Cueva-Méndez, G et al.. Repurposing a Prokaryotic Toxin-Antitoxin System for the Selective Killing of Oncogenically Stressed Human Cells. ACS Synth Biol. 2016;5 (7):540-6. doi: 10.1021/acssynbio.5b00096. PubMed PMID:26230535 .
Search PubMed
  1. Sanz-Viedma, S, Scholz Gutierrez, V, Fernández-Garcia, FJ, Jiménez-Hoyuela, JM. SPECT/CT lymphogammagraphy of a contralateral axillary drainage in a patient with breast cancer. Cir Esp. ;95 (6):348. doi: 10.1016/j.ciresp.2016.05.016. PubMed PMID:27364186 .
Search PubMed

Subscribe

Suscríbete a nuestro Newsletter y recibe en tu correo todas las últimas novedades del Instituto.
Consulta el histórico de Newsletter:

Calle Doctor Miguel Díaz Recio , 28 Málaga 29010

(+34) 951 440 260
Fax: (+34) 951 440 263